N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as fenretinide LXS, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing.
PURPOSE: This phase I trial is studying the side effects and best dose of fenretinide LXS in
treating patients with recurrent, refractory, or persistent neuroblastoma.